Kenneth Todd Moore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenneth Todd Moore has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
Jay Ariyawansa
7 shared publications- Veronica Ashton
Janssen Scientific Affairs, LLC
7 shared publications - Dominique Lejeune
Groupe d’analyse, Ltée, Montréal, Canada
5 shared publications - François Laliberté
Groupe d’analyse, SRI, Montréal, Canada
5 shared publications Akshay Kharat
Janssen Scientific Affairs, LLC., Titusville, USA
4 shared publicationsJaya Natarajan
Janssen Research & Development, LLC, Raritan, NJ
4 shared publications
Latest Publications
- 6 October 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (10)
A Brief Review of Vaccine History, Hesitancy, and Education Today
Vaccination remains one of the most effective global health interventions, preventing substantial morbidity and mortality and advancing population health worldwide. However, vaccine hesitancy continues to limit vaccine confidence and uptake in some communities. This brief review summarizes the historical, social, and educational factors shaping vaccine hesitancy and outlines practical strategies to improve confidence and uptake. Key contributors include safety concerns amplified by misinformation, the rapid spread of misleading content through social media, and residual mistrust related to rare past research abuses and manufacturing failures. Additional barriers include socioeconomic disadvantage, limited scientific literacy, religious influences, clustering of vaccine‐resistant beliefs, health inequities, and distrust of healthcare institutions. This review emphasizes that effective responses must extend beyond simply providing more information. Evidence supports dialogue‐based, tailored communication, transparent discussion of risks and benefits, empathetic parent–provider engagement, stronger vaccinology education for healthcare professionals, and improved access through combination vaccines, mobile clinics, and digital health tools. Addressing vaccine hesitancy requires coordinated, evidence‐based strategies centered on trust, communication, professional education, and equitable access to sustain public confidence in vaccination. As outlined in The American College of Clinical Pharmacology “Call to Action,” vaccine education is essential for safeguarding global health and trust in institutions involved in vaccine programs.
- 6 October 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (10)
A Brief Review of Vaccine History, Hesitancy, and Education Today
Vaccination remains one of the most effective global health interventions, preventing substantial morbidity and mortality and advancing population health worldwide. However, vaccine hesitancy continues to limit vaccine confidence and uptake in some communities. This brief review summarizes the historical, social, and educational factors shaping vaccine hesitancy and outlines practical strategies to improve confidence and uptake. Key contributors include safety concerns amplified by misinformation, the rapid spread of misleading content through social media, and residual mistrust related to rare past research abuses and manufacturing failures. Additional barriers include socioeconomic disadvantage, limited scientific literacy, religious influences, clustering of vaccine‐resistant beliefs, health inequities, and distrust of healthcare institutions. This review emphasizes that effective responses must extend beyond simply providing more information. Evidence supports dialogue‐based, tailored communication, transparent discussion of risks and benefits, empathetic parent–provider engagement, stronger vaccinology education for healthcare professionals, and improved access through combination vaccines, mobile clinics, and digital health tools. Addressing vaccine hesitancy requires coordinated, evidence‐based strategies centered on trust, communication, professional education, and equitable access to sustain public confidence in vaccination. As outlined in The American College of Clinical Pharmacology “Call to Action,” vaccine education is essential for safeguarding global health and trust in institutions involved in vaccine programs.
The Changing Application of Vulnerability Across the Different Phases of Clinical Research
The United States Food and Drug Omnibus Reform Act (FDORA) of 2022 established a legislative mandate requiring sponsors of pharmaceutical research to actively enhance the inclusion of historically underrepresented populations in clinical trials. This policy reflects the growing recognition that diversity in research is not only a scientific and medical necessity, but an ethical imperative rooted in the principle of justice. However, as efforts to increase diversity expand, the inclusion of individuals traditionally viewed as “vulnerable” introduces complex ethical considerations that necessitate a reassessment of current research practices. Historically, clinical research has often adopted an overly protective stance toward individuals classified as vulnerable, such as children, pregnant women, older adults, or those with cognitive or socioeconomic disadvantages, leading to their exclusion. This exclusion, while intended to prevent harm, paradoxically perpetuates inequalities restricting access to the potential benefits of research participation and evidence generation to support the broader use of the product. Moreover, this cautious approach is applied inconsistently across the phases of clinical development, suggesting a lack of ethical coherence in how vulnerability is defined, interpreted, and operationalized. A reexamination of the concept and treatment of vulnerability across all phases of clinical research is therefore essential. The consistent and ethically justified inclusion of vulnerable populations would advance the generalizability of scientific findings, promote health equity, and uphold the bioethical principles of autonomy, beneficence, nonmaleficence, and most critically, justice. Ensuring equitable inclusion is not merely a regulatory expectation but a moral obligation that underpins the legitimacy and integrity of clinical research.
The Changing Application of Vulnerability Across the Different Phases of Clinical Research
The United States Food and Drug Omnibus Reform Act (FDORA) of 2022 established a legislative mandate requiring sponsors of pharmaceutical research to actively enhance the inclusion of historically underrepresented populations in clinical trials. This policy reflects the growing recognition that diversity in research is not only a scientific and medical necessity, but an ethical imperative rooted in the principle of justice. However, as efforts to increase diversity expand, the inclusion of individuals traditionally viewed as “vulnerable” introduces complex ethical considerations that necessitate a reassessment of current research practices. Historically, clinical research has often adopted an overly protective stance toward individuals classified as vulnerable, such as children, pregnant women, older adults, or those with cognitive or socioeconomic disadvantages, leading to their exclusion. This exclusion, while intended to prevent harm, paradoxically perpetuates inequalities restricting access to the potential benefits of research participation and evidence generation to support the broader use of the product. Moreover, this cautious approach is applied inconsistently across the phases of clinical development, suggesting a lack of ethical coherence in how vulnerability is defined, interpreted, and operationalized. A reexamination of the concept and treatment of vulnerability across all phases of clinical research is therefore essential. The consistent and ethically justified inclusion of vulnerable populations would advance the generalizability of scientific findings, promote health equity, and uphold the bioethical principles of autonomy, beneficence, nonmaleficence, and most critically, justice. Ensuring equitable inclusion is not merely a regulatory expectation but a moral obligation that underpins the legitimacy and integrity of clinical research.
- 17 December 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (1) , e70146
The Importance of the Peer Review Process to Safeguard Scientific Integrity
- 17 December 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (1) , e70146
The Importance of the Peer Review Process to Safeguard Scientific Integrity
Clinical research vehicles as a modality for medical research education and conduct of decentralized trials, supporting justice, equity, and diversity in research
Current clinical research lacks diversity in those that participate. This lack of diversity is concerning given its importance for successful drug development. The frequency and severity of many diseases, along with the pharmacological properties of therapies, can display significant differences based on patient diversity. A clinical trial population that is more reflective of these differences will help researchers better understand the therapeutic profile of the treatment and provide generalizable knowledge to the medical community. The advent of decentralized clinical trial designs is meant to help address this lack of diversity by using portable digital health technologies and virtual interactions to enhance clinical trial access and broaden participation. By leveraging these technologies, trial conduct can occur at locations other than traditional research sites. This shift in trial location may help address some of the logistical, educational, engagement, and trust barriers that have historically prevented enrollment of diverse populations. However, these types of trials still have limitations. Ethical concerns around justice, equity, and diversity will still exist with decentralized clinical trials, which could be mediated using clinical research vehicles. When utilized, this modality may enhance the scientific design and conduct of clinical trials and better follow these ethical principles. These enhancements and improved ethical direction could be accomplished through increasing community involvement, improving health literacy, supporting more diverse trial sites, creating community‐based research footholds, fostering connections with researchers, limiting technical challenges, and preventing data security issues.
Clinical research vehicles as a modality for medical research education and conduct of decentralized trials, supporting justice, equity, and diversity in research
Current clinical research lacks diversity in those that participate. This lack of diversity is concerning given its importance for successful drug development. The frequency and severity of many diseases, along with the pharmacological properties of therapies, can display significant differences based on patient diversity. A clinical trial population that is more reflective of these differences will help researchers better understand the therapeutic profile of the treatment and provide generalizable knowledge to the medical community. The advent of decentralized clinical trial designs is meant to help address this lack of diversity by using portable digital health technologies and virtual interactions to enhance clinical trial access and broaden participation. By leveraging these technologies, trial conduct can occur at locations other than traditional research sites. This shift in trial location may help address some of the logistical, educational, engagement, and trust barriers that have historically prevented enrollment of diverse populations. However, these types of trials still have limitations. Ethical concerns around justice, equity, and diversity will still exist with decentralized clinical trials, which could be mediated using clinical research vehicles. When utilized, this modality may enhance the scientific design and conduct of clinical trials and better follow these ethical principles. These enhancements and improved ethical direction could be accomplished through increasing community involvement, improving health literacy, supporting more diverse trial sites, creating community‐based research footholds, fostering connections with researchers, limiting technical challenges, and preventing data security issues.
- 19 September 2024
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (2) , 153-159
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
- 19 September 2024
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (2) , 153-159
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
- Top Cited PapersOpen Access
- 16 February 2024
- Published by Springer Nature in Current Hypertension Reports
- Vol. 26 (5) , 183-199
Resistant Hypertension: Disease Burden and Emerging Treatment Options
Purpose of Review: To define resistant hypertension (RHT), review its pathophysiology and disease burden, identify barriers to effective hypertension management, and to highlight emerging treatment options. Recent Findings: RHT is defined as uncontrolled blood pressure (BP) ≥ 130/80 mm Hg despite concurrent prescription of ≥ 3 or ≥ 4 antihypertensive drugs in different classes or controlled BP despite prescription of ≥ to 4 drugs, at maximally tolerated doses, including a diuretic. BP is regulated by a complex interplay between the renin–angiotensin–aldosterone system, the sympathetic nervous system, the endothelin system, natriuretic peptides, the arterial vasculature, and the immune system; disruption of any of these can increase BP. RHT is disproportionately manifest in African Americans, older patients, and those with diabetes and/or chronic kidney disease (CKD). Amongst drug-treated hypertensives, only one-quarter have been treated intensively enough (prescribed > 2 drugs) to be considered for this diagnosis. New treatment strategies aimed at novel therapeutic targets include inhibition of sodium-glucose cotransporter 2, aminopeptidase A, aldosterone synthesis, phosphodiesterase 5, xanthine oxidase, and dopamine beta-hydroxylase, as well as soluble guanylate cyclase stimulation, nonsteroidal mineralocorticoid receptor antagonism, and dual endothelin receptor antagonism. Summary: The burden of RHT remains high. Better use of currently approved therapies and integrating emerging therapies are welcome additions to the therapeutic armamentarium for addressing needs in high-risk aTRH patients.
- 16 February 2024
- Published by Springer Nature in Current Hypertension Reports
- Vol. 26 (5) , 183-199
Top Cited PapersOpen AccessResistant Hypertension: Disease Burden and Emerging Treatment Options
Purpose of Review: To define resistant hypertension (RHT), review its pathophysiology and disease burden, identify barriers to effective hypertension management, and to highlight emerging treatment options. Recent Findings: RHT is defined as uncontrolled blood pressure (BP) ≥ 130/80 mm Hg despite concurrent prescription of ≥ 3 or ≥ 4 antihypertensive drugs in different classes or controlled BP despite prescription of ≥ to 4 drugs, at maximally tolerated doses, including a diuretic. BP is regulated by a complex interplay between the renin–angiotensin–aldosterone system, the sympathetic nervous system, the endothelin system, natriuretic peptides, the arterial vasculature, and the immune system; disruption of any of these can increase BP. RHT is disproportionately manifest in African Americans, older patients, and those with diabetes and/or chronic kidney disease (CKD). Amongst drug-treated hypertensives, only one-quarter have been treated intensively enough (prescribed > 2 drugs) to be considered for this diagnosis. New treatment strategies aimed at novel therapeutic targets include inhibition of sodium-glucose cotransporter 2, aminopeptidase A, aldosterone synthesis, phosphodiesterase 5, xanthine oxidase, and dopamine beta-hydroxylase, as well as soluble guanylate cyclase stimulation, nonsteroidal mineralocorticoid receptor antagonism, and dual endothelin receptor antagonism. Summary: The burden of RHT remains high. Better use of currently approved therapies and integrating emerging therapies are welcome additions to the therapeutic armamentarium for addressing needs in high-risk aTRH patients.
- 13 November 2023
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (1) , 13-18
Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action
- 13 November 2023
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (1) , 13-18
Inclusion of Obese Participants in Drug Development: Reflections on the Current Landscape and a Call for Action
- 9 November 2023
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 63 (S2) , S78-S84
The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development
Obesity remains a US national health crisis and a growing concern worldwide. Concerningly, individuals who are obese are at an increased risk for comorbid diseases that include, but are not limited to, hypertension, diabetes, cardiovascular disease, and cancer. Beyond the risk for developing these conditions, obesity may also impact the pharmacological activity of the therapies being used to treat them and other disease states. The pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of therapies, both currently marketed and under clinical development, may be directly impacted by the physiological alterations that occur secondary to the occurrence of chronic excess body weight. The increased prevalence of this disease should not be ignored. Both private and federal institutions involved in drug research and development should consider, as appropriate, a greater inclusion of individuals who are obese in clinical trials throughout the entirety of drug development, and leverage the available PK, PD, safety, and efficacy data to make more informed dosing recommendations.
- 9 November 2023
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 63 (S2) , S78-S84
The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development
Obesity remains a US national health crisis and a growing concern worldwide. Concerningly, individuals who are obese are at an increased risk for comorbid diseases that include, but are not limited to, hypertension, diabetes, cardiovascular disease, and cancer. Beyond the risk for developing these conditions, obesity may also impact the pharmacological activity of the therapies being used to treat them and other disease states. The pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of therapies, both currently marketed and under clinical development, may be directly impacted by the physiological alterations that occur secondary to the occurrence of chronic excess body weight. The increased prevalence of this disease should not be ignored. Both private and federal institutions involved in drug research and development should consider, as appropriate, a greater inclusion of individuals who are obese in clinical trials throughout the entirety of drug development, and leverage the available PK, PD, safety, and efficacy data to make more informed dosing recommendations.
- 29 September 2022
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (12) , 1475-1479
The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct
- 29 September 2022
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (12) , 1475-1479
The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct
- 22 September 2022
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (12) , 1465-1467
The Importance of Participant Tracking When Conducting Clinical Pharmacology Drug Trials
- 22 September 2022
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (12) , 1465-1467
The Importance of Participant Tracking When Conducting Clinical Pharmacology Drug Trials